texas oncology more breakthroughs. more victories
  • Request an Appointment
  • Find a cancer center
  • Find a provider
  • Clinical Trials

Share:

 
 

San Antonio Clinical Trials

Texas Oncology cancer centers in San Antonio participate in clinical trials and groundbreaking cancer research paving the way for new breakthroughs in cancer care. If you are a Texas Oncology patient in the San Antonio area, you may be able to take part in these innovative clinical trials.

Our San Antonio cancer centers offer several types of clinical trials:

  • Prevention trials focused on preventing cancer or recurrence. For example, the trial might focus on the use of vitamins, different medications or a change in diet or exercise to determine if the risk of developing cancer is lowered.
  • Screening trials focused on identifying and detecting cancer in people who do not exhibit symptoms of cancer.
  • Diagnostic trials determining how to identify cancers using new tests. Often, these trials involve participants who show signs or symptoms of a particular cancer.
  • Treatment trials designed to answer questions about new treatments, such as drugs, surgical procedures, vaccines, or therapies. They involve current cancer patients.

To review recent publications related to cancer research conducted by our physician, please click here.

Benefits and Risks

Discuss the benefits and risks with your physician if you're interested in participating in a clinical trial or cancer research in the San Antonio area. Benefits include being actively involved in your healthcare, getting access to new treatments and medical care, and helping to further medical research. Risks may include unpleasant or serious side effects, treatments that are ineffective, and trials which may take more time than standard treatment.

Eligibility

Your eligibility depends on several criteria, including your age and sex, your cancer type and stage of the the cancer, previous treatments, and your overall medical history. If you’re interested in participating in a clinical trial, view the list of open San Antonio trials below and talk to you doctor to determine which one may be right for you.

Principal Investigators

Biliary Cancer

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202) View

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202) View

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202) View

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202) View

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202) View

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202) View

Bladder Cancer

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma (MK-3475-361) View

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma (MK-3475-361) View

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma (MK-3475-361) View

Brain Cancer

Indication: Brain Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 View

Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: (USO 11025/ Novartis CBKM120ZUS39T) Phase II Multicenter Single-arm Study of BKM120 plus Capecitabine for Breast Cancer Patients with Brain Metastases View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: (USO 13033/ Millennium X14021) A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination with Paclitaxel vs. Paclitaxel Alone in Patients with Metastatic or Locally Recurrent Breast Cancer View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: (USO 13033/ Millennium X14021) A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination with Paclitaxel vs. Paclitaxel Alone in Patients with Metastatic or Locally Recurrent Breast Cancer View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: (USO 13033/ Millennium X14021) A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination with Paclitaxel vs. Paclitaxel Alone in Patients with Metastatic or Locally Recurrent Breast Cancer View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: I/II

Title: A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination with Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2- Advanced or Metastatic Breast Cancer That Has Progressed on Treatment with Everolimus in Combination with Exemestane or Fulvestrant (C31001) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: I/II

Title: A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination with Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2- Advanced or Metastatic Breast Cancer That Has Progressed on Treatment with Everolimus in Combination with Exemestane or Fulvestrant (C31001) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I/II

Title: A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination with Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2- Advanced or Metastatic Breast Cancer That Has Progressed on Treatment with Everolimus in Combination with Exemestane or Fulvestrant (C31001) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A PHASE I, MULTICENTER, OPEN-LABEL, MULTI-PART, DOSE-ESCALATION STUDY OF RAD1901 IN POSTMENOPAUSAL WOMEN WITH ADVANCED ESTROGEN RECEPTOR POSITIVE AND HER2-NEGATIVE BREAST CANCER - Radius Health RAD1901-005 View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors (VX12-970-001) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects with Advanced Breast Cancer.(INO-VT-464-CL-006) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects with Advanced Breast Cancer.(INO-VT-464-CL-006) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects with Advanced Breast Cancer.(INO-VT-464-CL-006) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects with Advanced Breast Cancer.(INO-VT-464-CL-006) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients with Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy (G1T28-04) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer (SGNLVA-001) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB) (ONT-380-206) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB) (ONT-380-206) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB) (ONT-380-206) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB) (ONT-380-206) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: A Phase III Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC) MK-3475-522 View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: A Phase III Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC) MK-3475-522 View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: A Phase III Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC) MK-3475-522 View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase:

Title: BREAKOUT -International Breast Cancer Biomarker, Standard of Care and Real World Outcomes Study (D0816R00012) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase:

Title: BREAKOUT -International Breast Cancer Biomarker, Standard of Care and Real World Outcomes Study (D0816R00012) View

Cervical Cancer

Indication: Cervical Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Cervical Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 View

Indication: Cervical Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Cervical Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Cervical Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Cervical Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Colon Cancer

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 View

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: A single arm, open-label, multicenter, multinational, safety and efficacy Phase IIIb trial of BI 695502 plus mFOLFOX6 in patients with previously untreated metastatic colorectal cancer (1302.3) View

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: A single arm, open-label, multicenter, multinational, safety and efficacy Phase IIIb trial of BI 695502 plus mFOLFOX6 in patients with previously untreated metastatic colorectal cancer (1302.3) View

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: A single arm, open-label, multicenter, multinational, safety and efficacy Phase IIIb trial of BI 695502 plus mFOLFOX6 in patients with previously untreated metastatic colorectal cancer (1302.3) View

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: A single arm, open-label, multicenter, multinational, safety and efficacy Phase IIIb trial of BI 695502 plus mFOLFOX6 in patients with previously untreated metastatic colorectal cancer (1302.3) View

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC) View

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC) View

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC) View

Endometrial Cancer

Indication: Endometrial Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Endometrial Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Endometrial Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Endometrial Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Endometrial Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Esophageal Cancer

Indication: Esophageal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Esophageal Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 View

Essential Thrombocythemia

Indication: Essential Thrombocythemia

Location: Texas Oncology-San Antonio Medical Center

Phase: IV

Title: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401) View

Fallopian Tube Cancer

Indication: Fallopian Tube Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Gall Bladder Cancer

Indication: Gall Bladder Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

GI Stromal Tumor (GIST)

Indication: GI Stromal Tumor (GIST)

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Head and Neck Cancer

Indication: Head and Neck Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Head and Neck Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Head and Neck Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Head and Neck Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Head and Neck Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Head and Neck Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Head and Neck Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Hematologic

Indication: Hematologic

Location: Texas Oncology-San Antonio Medical Center

Phase: IV

Title: PNH Registry (M07-001) View

Indication: Hematologic

Location: Texas Oncology-San Antonio Medical Center

Phase: IV

Title: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401) View

Leukemia

Indication: Leukemia

Location: Texas Oncology-San Antonio Downtown

Phase: IV

Title: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Stone Oak

Phase: IV

Title: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Northeast

Phase: IV

Title: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy (ACE-CL-208) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy (ACE-CL-208) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy (ACE-CL-208) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy (ACE-CL-208) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: (UTX-TGR-304) Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: (UTX-TGR-304) Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: (UTX-TGR-304) Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: (UTX-TGR-304) Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: (UTX-TGR-204) A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304 View

Indication: Leukemia

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: (UTX-TGR-204) A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304 View

Indication: Leukemia

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: (UTX-TGR-204) A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304 View

Indication: Leukemia

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: (UTX-TGR-204) A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304 View

Liver Cancer

Indication: Liver Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Liver Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 View

Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: CA209370: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: CA209370: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: CA209370: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III/IV

Title: A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks(CheckMate 384- CA209384) View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors (VX12-970-001) View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer - Ariad AP26113-13-301 View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer - Ariad AP26113-13-301 View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer - Ariad AP26113-13-301 View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer - Ariad AP26113-13-301 View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: SCRX001-004: A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients with Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIB/IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations (VISION) View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIB/IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations (VISION) View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIB/IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations (VISION) View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: HBI-8000-302: A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC) View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: (INCB 39110-207) An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) View

Lymphomas

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: PIX306: A Randomized Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed after Therapy with CHOP-R or an Equivalent Regimen and are Ineligible for Stem Cell Transplant View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: A PHASE 3B RANDOMIZED STUDY OF LENALIDOMIDE (CC-5013) PLUS RITUXIMAB MAINTENANCE THERAPY FOLLOWED BY LENALIDOMIDE SINGLE-AGENT MAINTENANCE VERSUS RITUXIMAB MAINTENANCE IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR, MARGINAL ZONE OR MANTLE CELL LYMPHOMA (CC-5013-NHL-008) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: A PHASE 3B RANDOMIZED STUDY OF LENALIDOMIDE (CC-5013) PLUS RITUXIMAB MAINTENANCE THERAPY FOLLOWED BY LENALIDOMIDE SINGLE-AGENT MAINTENANCE VERSUS RITUXIMAB MAINTENANCE IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR, MARGINAL ZONE OR MANTLE CELL LYMPHOMA (CC-5013-NHL-008) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: A PHASE 3B RANDOMIZED STUDY OF LENALIDOMIDE (CC-5013) PLUS RITUXIMAB MAINTENANCE THERAPY FOLLOWED BY LENALIDOMIDE SINGLE-AGENT MAINTENANCE VERSUS RITUXIMAB MAINTENANCE IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR, MARGINAL ZONE OR MANTLE CELL LYMPHOMA (CC-5013-NHL-008) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: A PHASE 3B RANDOMIZED STUDY OF LENALIDOMIDE (CC-5013) PLUS RITUXIMAB MAINTENANCE THERAPY FOLLOWED BY LENALIDOMIDE SINGLE-AGENT MAINTENANCE VERSUS RITUXIMAB MAINTENANCE IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR, MARGINAL ZONE OR MANTLE CELL LYMPHOMA (CC-5013-NHL-008) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Downtown

Phase: I

Title: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223,CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: I

Title: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223,CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223,CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223,CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma (UTX-TGR-205) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma (UTX-TGR-205) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma (UTX-TGR-205) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma (UTX-TGR-205) View

Melanoma

Indication: Melanoma

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 View

Indication: Melanoma

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: HBI-8000-302: A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC) View

Mesothelioma

Indication: Mesothelioma

Location: Texas Oncology-San Antonio Downtown

Phase: II/III

Title: Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed/cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed/cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma (1199.93) View

Indication: Mesothelioma

Location: Texas Oncology-San Antonio Stone Oak

Phase: II/III

Title: Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed/cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed/cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma (1199.93) View

Indication: Mesothelioma

Location: Texas Oncology-San Antonio Northeast

Phase: II/III

Title: Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed/cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed/cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma (1199.93) View

Indication: Mesothelioma

Location: Texas Oncology-San Antonio Medical Center

Phase: II/III

Title: Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed/cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed/cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma (1199.93) View

Indication: Mesothelioma

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Mesothelioma

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Mesothelioma

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Mesothelioma

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-San Antonio Medical Center

Phase: IV

Title: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401) View

Myelomas

Indication: Myelomas

Location: Texas Oncology-San Antonio Downtown

Phase:

Title: CA204-008: Prospective Research Assessment in Multiple Myeloma: an Observational Evaluation (PREAMBLE) View

Indication: Myelomas

Location: Texas Oncology-San Antonio Northeast

Phase:

Title: CA204-008: Prospective Research Assessment in Multiple Myeloma: an Observational Evaluation (PREAMBLE) View

Indication: Myelomas

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: CA204142:A Phase 2, Multiple Cohort Study of Elotuzumab in Combination with Pomalidomide and LowDose Dexamethasone (EPd), and in Combination with Nivolumab (EN), in Patients with Multiple Myeloma Relapsedor Refractory to Prior Treatment with Lenalidomide. View

Indication: Myelomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: CA204142:A Phase 2, Multiple Cohort Study of Elotuzumab in Combination with Pomalidomide and LowDose Dexamethasone (EPd), and in Combination with Nivolumab (EN), in Patients with Multiple Myeloma Relapsedor Refractory to Prior Treatment with Lenalidomide. View

Indication: Myelomas

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: CA204142:A Phase 2, Multiple Cohort Study of Elotuzumab in Combination with Pomalidomide and LowDose Dexamethasone (EPd), and in Combination with Nivolumab (EN), in Patients with Multiple Myeloma Relapsedor Refractory to Prior Treatment with Lenalidomide. View

Indication: Myelomas

Location: Texas Oncology-San Antonio Downtown

Phase: IV

Title: A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients - the INSIGHT MM study (NSMM-5001) View

Indication: Myelomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: IV

Title: A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients - the INSIGHT MM study (NSMM-5001) View

Indication: Myelomas

Location: Texas Oncology-San Antonio Northeast

Phase: IV

Title: A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients - the INSIGHT MM study (NSMM-5001) View

Indication: Myelomas

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: Daratumumab plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects with Multiple Myeloma (54767414MMY2012) View

Neuroendocrine Tumors

Indication: Neuroendocrine Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Neuroendocrine Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Neuroendocrine Tumors

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328 View

Indication: Neuroendocrine Tumors

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328 View

Indication: Neuroendocrine Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328 View

Indication: Neuroendocrine Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328 View

Indication: Neuroendocrine Tumors

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Neuroendocrine Tumors

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Neuroendocrine Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Neuroendocrine Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Ovarian Cancer

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: (ET743-OVC-3006) A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer View

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 View

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AND/OR FOLLOWING CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED EPITHELIAL OVARIAN CANCER (B9991010) View

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II/III

Title: FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician’s Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects with Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (OX4325) View

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: PR-30-5017-C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response On Front-Line Platinum-Based Chemotherapy (PRIMA) View

Pancreatic Cancer

Indication: Pancreatic Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Pancreatic Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Pancreatic Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: BBI608-118 (BBI608-201PANC): A Phase Ib Clinical Study of BBI608 in Combination with Standard Chemotherapies in Adult Patients with Metastatic Pancreatic Adenocarcinoma View

Indication: Pancreatic Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Pancreatic Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 View

Penile Cancer

Indication: Penile Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Penile Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Penile Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Penile Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Prostate Cancer

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: A Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy (SP005) View

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: A Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy (SP005) View

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: A Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy (SP005) View

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Rectal Cancer

Indication: Rectal Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Rectal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Rectal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Rectal Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 View

Indication: Rectal Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Rectal Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Rectal Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Rectal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Rectal Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC) View

Indication: Rectal Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC) View

Indication: Rectal Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC) View

Renal Cancer

Indication: Renal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Renal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: HBI-8000-302: A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC) View

Indication: Renal Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: A Phase III Randomized, Open-label, Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426) - Merck MK-3475-426 View

Indication: Renal Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: A Phase III Randomized, Open-label, Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426) - Merck MK-3475-426 View

Indication: Renal Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III/IV

Title: Phase 3b/4 Safety Trial Of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC (CA209-920) View

Indication: Renal Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III/IV

Title: Phase 3b/4 Safety Trial Of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC (CA209-920) View

Indication: Renal Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III/IV

Title: Phase 3b/4 Safety Trial Of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC (CA209-920) View

Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase Ib Clinical Study of BBI608 and BBI503 Administered in Combination to Adult Patients with Advanced Solid Tumors (BBI401-101) View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: A Phase Ib Clinical Study of BBI608 and BBI503 Administered in Combination to Adult Patients with Advanced Solid Tumors (BBI401-101) View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: I/II

Title: A Phase Ib/II Clinical Study of BBI503 in Combination with Selected Anti-Cancer Therapeutics in Adult Patients with Advanced Cancer - BBI503-201 View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Downtown

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Stone Oak

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Testicular Cancer

Indication: Testicular Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Testicular Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Testicular Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Testicular Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Testicular Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Thymomas

Indication: Thymomas

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thymomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thymomas

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thymomas

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Thyroid Cancer

Indication: Thyroid Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thyroid Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thyroid Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thyroid Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Urothelial Cancer

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma (MK-3475-361) View

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma (MK-3475-361) View

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma (MK-3475-361) View

Uterine Cancer

Indication: Uterine Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Uterine Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Uterine Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Uterine Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Vaginal Cancer

Indication: Vaginal Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Vaginal Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Vaginal Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Vaginal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Texas Oncology-San Antonio Downtown

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202) View

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma (MK-3475-361) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: (USO 13033/ Millennium X14021) A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination with Paclitaxel vs. Paclitaxel Alone in Patients with Metastatic or Locally Recurrent Breast Cancer View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: I/II

Title: A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination with Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2- Advanced or Metastatic Breast Cancer That Has Progressed on Treatment with Everolimus in Combination with Exemestane or Fulvestrant (C31001) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects with Advanced Breast Cancer.(INO-VT-464-CL-006) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB) (ONT-380-206) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: A Phase III Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC) MK-3475-522 View

Indication: Cervical Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: A single arm, open-label, multicenter, multinational, safety and efficacy Phase IIIb trial of BI 695502 plus mFOLFOX6 in patients with previously untreated metastatic colorectal cancer (1302.3) View

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC) View

Indication: Endometrial Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Head and Neck Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Downtown

Phase: IV

Title: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy (ACE-CL-208) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: (UTX-TGR-304) Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: (UTX-TGR-204) A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304 View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: CA209370: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III/IV

Title: A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks(CheckMate 384- CA209384) View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer - Ariad AP26113-13-301 View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIB/IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations (VISION) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: A PHASE 3B RANDOMIZED STUDY OF LENALIDOMIDE (CC-5013) PLUS RITUXIMAB MAINTENANCE THERAPY FOLLOWED BY LENALIDOMIDE SINGLE-AGENT MAINTENANCE VERSUS RITUXIMAB MAINTENANCE IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR, MARGINAL ZONE OR MANTLE CELL LYMPHOMA (CC-5013-NHL-008) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Downtown

Phase: I

Title: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223,CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma (UTX-TGR-205) View

Indication: Mesothelioma

Location: Texas Oncology-San Antonio Downtown

Phase: II/III

Title: Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed/cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed/cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma (1199.93) View

Indication: Mesothelioma

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Myelomas

Location: Texas Oncology-San Antonio Downtown

Phase:

Title: CA204-008: Prospective Research Assessment in Multiple Myeloma: an Observational Evaluation (PREAMBLE) View

Indication: Myelomas

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: CA204142:A Phase 2, Multiple Cohort Study of Elotuzumab in Combination with Pomalidomide and LowDose Dexamethasone (EPd), and in Combination with Nivolumab (EN), in Patients with Multiple Myeloma Relapsedor Refractory to Prior Treatment with Lenalidomide. View

Indication: Myelomas

Location: Texas Oncology-San Antonio Downtown

Phase: IV

Title: A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients - the INSIGHT MM study (NSMM-5001) View

Indication: Neuroendocrine Tumors

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328 View

Indication: Neuroendocrine Tumors

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Penile Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: A Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy (SP005) View

Indication: Rectal Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Rectal Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC) View

Indication: Renal Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III/IV

Title: Phase 3b/4 Safety Trial Of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC (CA209-920) View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Downtown

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Testicular Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thymomas

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thyroid Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma (MK-3475-361) View

Indication: Uterine Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Vaginal Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Texas Oncology-San Antonio Medical Center

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202) View

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202) View

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors (VX12-970-001) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects with Advanced Breast Cancer.(INO-VT-464-CL-006) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB) (ONT-380-206) View

Indication: Cervical Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Cervical Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: A single arm, open-label, multicenter, multinational, safety and efficacy Phase IIIb trial of BI 695502 plus mFOLFOX6 in patients with previously untreated metastatic colorectal cancer (1302.3) View

Indication: Endometrial Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Endometrial Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Esophageal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Essential Thrombocythemia

Location: Texas Oncology-San Antonio Medical Center

Phase: IV

Title: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401) View

Indication: Fallopian Tube Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Gall Bladder Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: GI Stromal Tumor (GIST)

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Head and Neck Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Head and Neck Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Head and Neck Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Hematologic

Location: Texas Oncology-San Antonio Medical Center

Phase: IV

Title: PNH Registry (M07-001) View

Indication: Hematologic

Location: Texas Oncology-San Antonio Medical Center

Phase: IV

Title: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy (ACE-CL-208) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: (UTX-TGR-304) Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: (UTX-TGR-204) A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304 View

Indication: Liver Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors (VX12-970-001) View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer - Ariad AP26113-13-301 View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: SCRX001-004: A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients with Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: HBI-8000-302: A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC) View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: (INCB 39110-207) An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: PIX306: A Randomized Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed after Therapy with CHOP-R or an Equivalent Regimen and are Ineligible for Stem Cell Transplant View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: A PHASE 3B RANDOMIZED STUDY OF LENALIDOMIDE (CC-5013) PLUS RITUXIMAB MAINTENANCE THERAPY FOLLOWED BY LENALIDOMIDE SINGLE-AGENT MAINTENANCE VERSUS RITUXIMAB MAINTENANCE IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR, MARGINAL ZONE OR MANTLE CELL LYMPHOMA (CC-5013-NHL-008) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223,CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma (UTX-TGR-205) View

Indication: Melanoma

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: HBI-8000-302: A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC) View

Indication: Mesothelioma

Location: Texas Oncology-San Antonio Medical Center

Phase: II/III

Title: Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed/cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed/cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma (1199.93) View

Indication: Mesothelioma

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Myelofibrosis

Location: Texas Oncology-San Antonio Medical Center

Phase: IV

Title: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401) View

Indication: Myelomas

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: Daratumumab plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects with Multiple Myeloma (54767414MMY2012) View

Indication: Neuroendocrine Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Neuroendocrine Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328 View

Indication: Neuroendocrine Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: (ET743-OVC-3006) A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer View

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AND/OR FOLLOWING CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED EPITHELIAL OVARIAN CANCER (B9991010) View

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II/III

Title: FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician’s Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects with Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (OX4325) View

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: PR-30-5017-C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response On Front-Line Platinum-Based Chemotherapy (PRIMA) View

Indication: Pancreatic Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Pancreatic Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Penile Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Rectal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Rectal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Rectal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Renal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Renal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: HBI-8000-302: A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC) View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: A Phase Ib Clinical Study of BBI608 and BBI503 Administered in Combination to Adult Patients with Advanced Solid Tumors (BBI401-101) View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Testicular Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Testicular Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thymomas

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thyroid Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Uterine Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Vaginal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Texas Oncology-San Antonio Northeast

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202) View

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202) View

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma (MK-3475-361) View

Indication: Brain Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: (USO 11025/ Novartis CBKM120ZUS39T) Phase II Multicenter Single-arm Study of BKM120 plus Capecitabine for Breast Cancer Patients with Brain Metastases View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: (USO 13033/ Millennium X14021) A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination with Paclitaxel vs. Paclitaxel Alone in Patients with Metastatic or Locally Recurrent Breast Cancer View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I/II

Title: A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination with Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2- Advanced or Metastatic Breast Cancer That Has Progressed on Treatment with Everolimus in Combination with Exemestane or Fulvestrant (C31001) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A PHASE I, MULTICENTER, OPEN-LABEL, MULTI-PART, DOSE-ESCALATION STUDY OF RAD1901 IN POSTMENOPAUSAL WOMEN WITH ADVANCED ESTROGEN RECEPTOR POSITIVE AND HER2-NEGATIVE BREAST CANCER - Radius Health RAD1901-005 View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects with Advanced Breast Cancer.(INO-VT-464-CL-006) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients with Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy (G1T28-04) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer (SGNLVA-001) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB) (ONT-380-206) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: A Phase III Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC) MK-3475-522 View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase:

Title: BREAKOUT -International Breast Cancer Biomarker, Standard of Care and Real World Outcomes Study (D0816R00012) View

Indication: Cervical Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 View

Indication: Cervical Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 View

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: A single arm, open-label, multicenter, multinational, safety and efficacy Phase IIIb trial of BI 695502 plus mFOLFOX6 in patients with previously untreated metastatic colorectal cancer (1302.3) View

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC) View

Indication: Endometrial Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Esophageal Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 View

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Head and Neck Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Head and Neck Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Northeast

Phase: IV

Title: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy (ACE-CL-208) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: (UTX-TGR-304) Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: (UTX-TGR-204) A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304 View

Indication: Liver Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: CA209370: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer - Ariad AP26113-13-301 View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIB/IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations (VISION) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: A PHASE 3B RANDOMIZED STUDY OF LENALIDOMIDE (CC-5013) PLUS RITUXIMAB MAINTENANCE THERAPY FOLLOWED BY LENALIDOMIDE SINGLE-AGENT MAINTENANCE VERSUS RITUXIMAB MAINTENANCE IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR, MARGINAL ZONE OR MANTLE CELL LYMPHOMA (CC-5013-NHL-008) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223,CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma (UTX-TGR-205) View

Indication: Melanoma

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 View

Indication: Mesothelioma

Location: Texas Oncology-San Antonio Northeast

Phase: II/III

Title: Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed/cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed/cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma (1199.93) View

Indication: Mesothelioma

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Myelomas

Location: Texas Oncology-San Antonio Northeast

Phase:

Title: CA204-008: Prospective Research Assessment in Multiple Myeloma: an Observational Evaluation (PREAMBLE) View

Indication: Myelomas

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: CA204142:A Phase 2, Multiple Cohort Study of Elotuzumab in Combination with Pomalidomide and LowDose Dexamethasone (EPd), and in Combination with Nivolumab (EN), in Patients with Multiple Myeloma Relapsedor Refractory to Prior Treatment with Lenalidomide. View

Indication: Myelomas

Location: Texas Oncology-San Antonio Northeast

Phase: IV

Title: A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients - the INSIGHT MM study (NSMM-5001) View

Indication: Neuroendocrine Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Neuroendocrine Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328 View

Indication: Neuroendocrine Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 View

Indication: Pancreatic Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Pancreatic Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: BBI608-118 (BBI608-201PANC): A Phase Ib Clinical Study of BBI608 in Combination with Standard Chemotherapies in Adult Patients with Metastatic Pancreatic Adenocarcinoma View

Indication: Pancreatic Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 View

Indication: Penile Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: A Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy (SP005) View

Indication: Rectal Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Rectal Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 View

Indication: Rectal Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Rectal Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC) View

Indication: Renal Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: A Phase III Randomized, Open-label, Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426) - Merck MK-3475-426 View

Indication: Renal Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III/IV

Title: Phase 3b/4 Safety Trial Of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC (CA209-920) View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase Ib Clinical Study of BBI608 and BBI503 Administered in Combination to Adult Patients with Advanced Solid Tumors (BBI401-101) View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: I/II

Title: A Phase Ib/II Clinical Study of BBI503 in Combination with Selected Anti-Cancer Therapeutics in Adult Patients with Advanced Cancer - BBI503-201 View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Testicular Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thymomas

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thyroid Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma (MK-3475-361) View

Indication: Uterine Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Vaginal Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Texas Oncology-San Antonio Stone Oak

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202) View

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma (MK-3475-361) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: (USO 13033/ Millennium X14021) A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination with Paclitaxel vs. Paclitaxel Alone in Patients with Metastatic or Locally Recurrent Breast Cancer View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: I/II

Title: A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination with Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2- Advanced or Metastatic Breast Cancer That Has Progressed on Treatment with Everolimus in Combination with Exemestane or Fulvestrant (C31001) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects with Advanced Breast Cancer.(INO-VT-464-CL-006) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB) (ONT-380-206) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: A Phase III Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC) MK-3475-522 View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase:

Title: BREAKOUT -International Breast Cancer Biomarker, Standard of Care and Real World Outcomes Study (D0816R00012) View

Indication: Cervical Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: A single arm, open-label, multicenter, multinational, safety and efficacy Phase IIIb trial of BI 695502 plus mFOLFOX6 in patients with previously untreated metastatic colorectal cancer (1302.3) View

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC) View

Indication: Endometrial Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Head and Neck Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Stone Oak

Phase: IV

Title: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy (ACE-CL-208) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: (UTX-TGR-304) Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: (UTX-TGR-204) A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304 View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: CA209370: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer - Ariad AP26113-13-301 View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIB/IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations (VISION) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: A PHASE 3B RANDOMIZED STUDY OF LENALIDOMIDE (CC-5013) PLUS RITUXIMAB MAINTENANCE THERAPY FOLLOWED BY LENALIDOMIDE SINGLE-AGENT MAINTENANCE VERSUS RITUXIMAB MAINTENANCE IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR, MARGINAL ZONE OR MANTLE CELL LYMPHOMA (CC-5013-NHL-008) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: I

Title: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223,CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma (UTX-TGR-205) View

Indication: Mesothelioma

Location: Texas Oncology-San Antonio Stone Oak

Phase: II/III

Title: Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed/cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed/cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma (1199.93) View

Indication: Mesothelioma

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Myelomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: CA204142:A Phase 2, Multiple Cohort Study of Elotuzumab in Combination with Pomalidomide and LowDose Dexamethasone (EPd), and in Combination with Nivolumab (EN), in Patients with Multiple Myeloma Relapsedor Refractory to Prior Treatment with Lenalidomide. View

Indication: Myelomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: IV

Title: A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients - the INSIGHT MM study (NSMM-5001) View

Indication: Neuroendocrine Tumors

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328 View

Indication: Neuroendocrine Tumors

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Penile Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: A Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy (SP005) View

Indication: Rectal Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Rectal Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC) View

Indication: Renal Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: A Phase III Randomized, Open-label, Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426) - Merck MK-3475-426 View

Indication: Renal Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III/IV

Title: Phase 3b/4 Safety Trial Of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC (CA209-920) View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Stone Oak

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Testicular Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thymomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thyroid Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma (MK-3475-361) View

Indication: Uterine Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Vaginal Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

No Phase

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase:

Title: BREAKOUT -International Breast Cancer Biomarker, Standard of Care and Real World Outcomes Study (D0816R00012) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase:

Title: BREAKOUT -International Breast Cancer Biomarker, Standard of Care and Real World Outcomes Study (D0816R00012) View

Indication: Myelomas

Location: Texas Oncology-San Antonio Downtown

Phase:

Title: CA204-008: Prospective Research Assessment in Multiple Myeloma: an Observational Evaluation (PREAMBLE) View

Indication: Myelomas

Location: Texas Oncology-San Antonio Northeast

Phase:

Title: CA204-008: Prospective Research Assessment in Multiple Myeloma: an Observational Evaluation (PREAMBLE) View

Phase I

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Brain Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A PHASE I, MULTICENTER, OPEN-LABEL, MULTI-PART, DOSE-ESCALATION STUDY OF RAD1901 IN POSTMENOPAUSAL WOMEN WITH ADVANCED ESTROGEN RECEPTOR POSITIVE AND HER2-NEGATIVE BREAST CANCER - Radius Health RAD1901-005 View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors (VX12-970-001) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer (SGNLVA-001) View

Indication: Cervical Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 View

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 View

Indication: Esophageal Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 View

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Head and Neck Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Head and Neck Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Liver Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors (VX12-970-001) View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Downtown

Phase: I

Title: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223,CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: I

Title: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223,CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223,CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223,CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001) View

Indication: Melanoma

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 View

Indication: Neuroendocrine Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Neuroendocrine Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 View

Indication: Pancreatic Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Pancreatic Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Pancreatic Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: BBI608-118 (BBI608-201PANC): A Phase Ib Clinical Study of BBI608 in Combination with Standard Chemotherapies in Adult Patients with Metastatic Pancreatic Adenocarcinoma View

Indication: Pancreatic Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 View

Indication: Rectal Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Rectal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: A Phase 1 Clinical Study of BBI503 in Adult Patients with Advanced Solid Tumors (BBI503-101) View

Indication: Rectal Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase Ib Clinical Study of BBI608 and BBI503 Administered in Combination to Adult Patients with Advanced Solid Tumors (BBI401-101) View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: I

Title: A Phase Ib Clinical Study of BBI608 and BBI503 Administered in Combination to Adult Patients with Advanced Solid Tumors (BBI401-101) View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001 View

Phase I/II

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: I/II

Title: A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination with Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2- Advanced or Metastatic Breast Cancer That Has Progressed on Treatment with Everolimus in Combination with Exemestane or Fulvestrant (C31001) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: I/II

Title: A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination with Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2- Advanced or Metastatic Breast Cancer That Has Progressed on Treatment with Everolimus in Combination with Exemestane or Fulvestrant (C31001) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: I/II

Title: A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination with Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2- Advanced or Metastatic Breast Cancer That Has Progressed on Treatment with Everolimus in Combination with Exemestane or Fulvestrant (C31001) View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: SCRX001-004: A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients with Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: HBI-8000-302: A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC) View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: (INCB 39110-207) An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) View

Indication: Melanoma

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: HBI-8000-302: A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC) View

Indication: Renal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: I/II

Title: HBI-8000-302: A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC) View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: I/II

Title: A Phase Ib/II Clinical Study of BBI503 in Combination with Selected Anti-Cancer Therapeutics in Adult Patients with Advanced Cancer - BBI503-201 View

Phase II

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202) View

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202) View

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202) View

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202) View

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202) View

Indication: Biliary Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202) View

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: (USO 11025/ Novartis CBKM120ZUS39T) Phase II Multicenter Single-arm Study of BKM120 plus Capecitabine for Breast Cancer Patients with Brain Metastases View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: (USO 13033/ Millennium X14021) A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination with Paclitaxel vs. Paclitaxel Alone in Patients with Metastatic or Locally Recurrent Breast Cancer View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: (USO 13033/ Millennium X14021) A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination with Paclitaxel vs. Paclitaxel Alone in Patients with Metastatic or Locally Recurrent Breast Cancer View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: (USO 13033/ Millennium X14021) A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination with Paclitaxel vs. Paclitaxel Alone in Patients with Metastatic or Locally Recurrent Breast Cancer View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects with Advanced Breast Cancer.(INO-VT-464-CL-006) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects with Advanced Breast Cancer.(INO-VT-464-CL-006) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects with Advanced Breast Cancer.(INO-VT-464-CL-006) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects with Advanced Breast Cancer.(INO-VT-464-CL-006) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients with Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy (G1T28-04) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB) (ONT-380-206) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB) (ONT-380-206) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB) (ONT-380-206) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB) (ONT-380-206) View

Indication: Cervical Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Cervical Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Cervical Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Cervical Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Endometrial Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Endometrial Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Endometrial Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Endometrial Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Head and Neck Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Head and Neck Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Head and Neck Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Head and Neck Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy (ACE-CL-208) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy (ACE-CL-208) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy (ACE-CL-208) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy (ACE-CL-208) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: (UTX-TGR-204) A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304 View

Indication: Leukemia

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: (UTX-TGR-204) A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304 View

Indication: Leukemia

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: (UTX-TGR-204) A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304 View

Indication: Leukemia

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: (UTX-TGR-204) A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304 View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: CA209370: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: CA209370: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: CA209370: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIB/IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations (VISION) View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIB/IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations (VISION) View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIB/IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations (VISION) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma (UTX-TGR-205) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma (UTX-TGR-205) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma (UTX-TGR-205) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma (UTX-TGR-205) View

Indication: Mesothelioma

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Mesothelioma

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Mesothelioma

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Mesothelioma

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Myelomas

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: CA204142:A Phase 2, Multiple Cohort Study of Elotuzumab in Combination with Pomalidomide and LowDose Dexamethasone (EPd), and in Combination with Nivolumab (EN), in Patients with Multiple Myeloma Relapsedor Refractory to Prior Treatment with Lenalidomide. View

Indication: Myelomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: CA204142:A Phase 2, Multiple Cohort Study of Elotuzumab in Combination with Pomalidomide and LowDose Dexamethasone (EPd), and in Combination with Nivolumab (EN), in Patients with Multiple Myeloma Relapsedor Refractory to Prior Treatment with Lenalidomide. View

Indication: Myelomas

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: CA204142:A Phase 2, Multiple Cohort Study of Elotuzumab in Combination with Pomalidomide and LowDose Dexamethasone (EPd), and in Combination with Nivolumab (EN), in Patients with Multiple Myeloma Relapsedor Refractory to Prior Treatment with Lenalidomide. View

Indication: Myelomas

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: Daratumumab plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects with Multiple Myeloma (54767414MMY2012) View

Indication: Neuroendocrine Tumors

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Neuroendocrine Tumors

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Neuroendocrine Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Neuroendocrine Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Penile Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Penile Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Penile Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Penile Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Rectal Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Rectal Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Rectal Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Rectal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Testicular Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Testicular Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Testicular Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Testicular Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thymomas

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thymomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thymomas

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thymomas

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thyroid Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thyroid Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thyroid Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thyroid Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Uterine Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Uterine Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Uterine Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Uterine Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Vaginal Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Vaginal Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Vaginal Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Vaginal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Phase II/III

Indication: Mesothelioma

Location: Texas Oncology-San Antonio Downtown

Phase: II/III

Title: Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed/cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed/cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma (1199.93) View

Indication: Mesothelioma

Location: Texas Oncology-San Antonio Stone Oak

Phase: II/III

Title: Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed/cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed/cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma (1199.93) View

Indication: Mesothelioma

Location: Texas Oncology-San Antonio Northeast

Phase: II/III

Title: Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed/cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed/cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma (1199.93) View

Indication: Mesothelioma

Location: Texas Oncology-San Antonio Medical Center

Phase: II/III

Title: Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed/cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed/cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma (1199.93) View

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: II/III

Title: FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician’s Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects with Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (OX4325) View

Phase III

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma (MK-3475-361) View

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma (MK-3475-361) View

Indication: Bladder Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma (MK-3475-361) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003) View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: A Phase III Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC) MK-3475-522 View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: A Phase III Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC) MK-3475-522 View

Indication: Breast Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: A Phase III Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC) MK-3475-522 View

Indication: Cervical Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: A single arm, open-label, multicenter, multinational, safety and efficacy Phase IIIb trial of BI 695502 plus mFOLFOX6 in patients with previously untreated metastatic colorectal cancer (1302.3) View

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: A single arm, open-label, multicenter, multinational, safety and efficacy Phase IIIb trial of BI 695502 plus mFOLFOX6 in patients with previously untreated metastatic colorectal cancer (1302.3) View

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: A single arm, open-label, multicenter, multinational, safety and efficacy Phase IIIb trial of BI 695502 plus mFOLFOX6 in patients with previously untreated metastatic colorectal cancer (1302.3) View

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: A single arm, open-label, multicenter, multinational, safety and efficacy Phase IIIb trial of BI 695502 plus mFOLFOX6 in patients with previously untreated metastatic colorectal cancer (1302.3) View

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC) View

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC) View

Indication: Colon Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC) View

Indication: Endometrial Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Esophageal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Fallopian Tube Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Gall Bladder Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Gastric Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: GI Stromal Tumor (GIST)

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Head and Neck Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: (UTX-TGR-304) Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: (UTX-TGR-304) Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: (UTX-TGR-304) Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: (UTX-TGR-304) Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) View

Indication: Liver Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer - Ariad AP26113-13-301 View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer - Ariad AP26113-13-301 View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer - Ariad AP26113-13-301 View

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer - Ariad AP26113-13-301 View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: PIX306: A Randomized Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed after Therapy with CHOP-R or an Equivalent Regimen and are Ineligible for Stem Cell Transplant View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: A PHASE 3B RANDOMIZED STUDY OF LENALIDOMIDE (CC-5013) PLUS RITUXIMAB MAINTENANCE THERAPY FOLLOWED BY LENALIDOMIDE SINGLE-AGENT MAINTENANCE VERSUS RITUXIMAB MAINTENANCE IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR, MARGINAL ZONE OR MANTLE CELL LYMPHOMA (CC-5013-NHL-008) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: A PHASE 3B RANDOMIZED STUDY OF LENALIDOMIDE (CC-5013) PLUS RITUXIMAB MAINTENANCE THERAPY FOLLOWED BY LENALIDOMIDE SINGLE-AGENT MAINTENANCE VERSUS RITUXIMAB MAINTENANCE IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR, MARGINAL ZONE OR MANTLE CELL LYMPHOMA (CC-5013-NHL-008) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: A PHASE 3B RANDOMIZED STUDY OF LENALIDOMIDE (CC-5013) PLUS RITUXIMAB MAINTENANCE THERAPY FOLLOWED BY LENALIDOMIDE SINGLE-AGENT MAINTENANCE VERSUS RITUXIMAB MAINTENANCE IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR, MARGINAL ZONE OR MANTLE CELL LYMPHOMA (CC-5013-NHL-008) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: A PHASE 3B RANDOMIZED STUDY OF LENALIDOMIDE (CC-5013) PLUS RITUXIMAB MAINTENANCE THERAPY FOLLOWED BY LENALIDOMIDE SINGLE-AGENT MAINTENANCE VERSUS RITUXIMAB MAINTENANCE IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR, MARGINAL ZONE OR MANTLE CELL LYMPHOMA (CC-5013-NHL-008) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Lymphomas

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204) View

Indication: Neuroendocrine Tumors

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328 View

Indication: Neuroendocrine Tumors

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328 View

Indication: Neuroendocrine Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328 View

Indication: Neuroendocrine Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328 View

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: (ET743-OVC-3006) A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer View

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AND/OR FOLLOWING CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED EPITHELIAL OVARIAN CANCER (B9991010) View

Indication: Ovarian Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: PR-30-5017-C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response On Front-Line Platinum-Based Chemotherapy (PRIMA) View

Indication: Pancreatic Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: A Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy (SP005) View

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: A Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy (SP005) View

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: A Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy (SP005) View

Indication: Prostate Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Rectal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Rectal Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC) View

Indication: Rectal Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC) View

Indication: Rectal Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC) View

Indication: Renal Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Renal Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: A Phase III Randomized, Open-label, Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426) - Merck MK-3475-426 View

Indication: Renal Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: A Phase III Randomized, Open-label, Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426) - Merck MK-3475-426 View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Testicular Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Location: Texas Oncology-San Antonio Medical Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III

Title: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma (MK-3475-361) View

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III

Title: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma (MK-3475-361) View

Indication: Urothelial Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III

Title: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma (MK-3475-361) View

Phase III/IV

Indication: Lung Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III/IV

Title: A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks(CheckMate 384- CA209384) View

Indication: Renal Cancer

Location: Texas Oncology-San Antonio Downtown

Phase: III/IV

Title: Phase 3b/4 Safety Trial Of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC (CA209-920) View

Indication: Renal Cancer

Location: Texas Oncology-San Antonio Stone Oak

Phase: III/IV

Title: Phase 3b/4 Safety Trial Of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC (CA209-920) View

Indication: Renal Cancer

Location: Texas Oncology-San Antonio Northeast

Phase: III/IV

Title: Phase 3b/4 Safety Trial Of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC (CA209-920) View

Phase IV

Indication: Essential Thrombocythemia

Location: Texas Oncology-San Antonio Medical Center

Phase: IV

Title: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401) View

Indication: Hematologic

Location: Texas Oncology-San Antonio Medical Center

Phase: IV

Title: PNH Registry (M07-001) View

Indication: Hematologic

Location: Texas Oncology-San Antonio Medical Center

Phase: IV

Title: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Downtown

Phase: IV

Title: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Stone Oak

Phase: IV

Title: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA) View

Indication: Leukemia

Location: Texas Oncology-San Antonio Northeast

Phase: IV

Title: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA) View

Indication: Myelofibrosis

Location: Texas Oncology-San Antonio Medical Center

Phase: IV

Title: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401) View

Indication: Myelomas

Location: Texas Oncology-San Antonio Downtown

Phase: IV

Title: A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients - the INSIGHT MM study (NSMM-5001) View

Indication: Myelomas

Location: Texas Oncology-San Antonio Stone Oak

Phase: IV

Title: A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients - the INSIGHT MM study (NSMM-5001) View

Indication: Myelomas

Location: Texas Oncology-San Antonio Northeast

Phase: IV

Title: A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients - the INSIGHT MM study (NSMM-5001) View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Downtown

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Stone Oak

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Northeast

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-San Antonio Medical Center

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View